natgillin/translations-raw huggingface dataset:
EU/1/08/503/008 14 film-coated tablets EU/1/08/503/009 28 film-coated tablets EU/1/08/503/010 30x1 film-coated tablet EU/1/08/503/011 56 film-coated tablets EU/1/08/503/012 84 film-coated tablets EU/1/08/503/013 90x1 film-coated tablet EU/1/08/503/014 98 film-coated tablets EU/1/08/503/016 30 film-coated tablets 
EU/1/08/503/008 14 filmom obloženih tableta EU/1/08/503/009 28 filmom obloženih tableta EU/1/08/503/010 30x1 filmom obložena tableta EU/1/08/503/011 56 filmom obloženih tableta EU/1/08/503/012 84 filmom obložene tablete EU/1/08/503/013 90x1 filmom obložena tableta EU/1/08/503/014 98 filmom obložene tablete EU/1/08/503/016 30 filmom obložene tablete
LIST OF EXCIPIENTS Contains lactose. 
POPIS POMOĆNIH TVARI Sadrži laktozu.
Prasugrel had no effect on fertility of male and female rats at oral doses up to an exposure 240 times the recommended daily human maintenance dose (based on mg/m2). 
Plodnost Prasugrel nije utjecao na plodnost mužjaka i ženki štakora koji su primali peroralne doze do izloženosti 240 puta veće od one u ljudi uz primjenu preporučene dnevne doze održavanja (na temelju mg/m2).
Patients randomised to receive prasugrel (60 mg loading dose followed by 10 mg once daily) or clopidogrel (300 mg loading dose followed by 75 mg once daily) were treated for a median of 14.5 months (maximum of 15 months with a minimum of 6 months follow-up). 
Bolesnici su randomizirani da primaju prasugrel (udarna doza od 60 mg, a zatim 10 mg jedanput na dan) ili klopidogrel (udarna doza od 300 mg, a zatim 75 mg jedanput na dan) te su liječeni tijekom medijana od 14,5 mjeseci (najviše 15 mjeseci uz najmanje 6 mjeseci praćenja nakon liječenja).
Because of the potential for increased risk of bleeding, warfarin (or other coumarin derivatives) and prasugrel should be co-administered with caution (see section 4.4). 
Zbog mogućeg povećanog rizika od krvarenja, istodobna primjena varfarina (ili drugih derivata kumarina) i prasugrela mora se odvijati uz oprez (vidjeti dio 4.4).
Efient was administered without regard to food in TRITON. 
Efient se u ispitivanju TRITON primjenjivao neovisno o obroku.
Following a 60 mg loading dose of prasugrel, inhibition of ADP-induced platelet aggregation occurs at 15 minutes with 5 µM ADP and 30 minutes with 20 µM ADP. 
Po primjeni udarne doze od 60 mg prasugrela inhibicija ADP-om potaknute agregacije trombocita nastupa nakon 15 minuta uz 5 µm ADP-a, a nakon 30 minuta uz 20 µm ADP-a.
No dose adjustment is necessary in subjects with mild to moderate hepatic impairment (Child Pugh class A and B) (see section 5.2). 
Nije potrebno prilagođavati dozu u osoba s blagim do umjerenim oštećenjem jetre (Child-Pugh stadij A i B) (vidjeti dio 5.2).
The observed benefit of prasugrel in patients ≥ 75 years was less than that observed in patients < 75 years. 
Korist liječenja prasugrelom u bolesnika u dobi od ≥ 75 godina bila je manja od one u bolesnika mlađih od 75 godina.
More than 98% of subjects had ≥ 20% inhibition of platelet aggregation during maintenance dosing. 
U više od 98% ispitanika je tijekom primjene doze održavanja postignuta inhibicija agregacije trombocita od ≥ 20%.
Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject (9%) and within-subject (12%) variability with both 5 µM and 20 µM ADP. 
Prasugrelom posredovana inhibicija agregacije trombocita iskazuje nisku interindividualnu (9%) i intraindividualnu (12%) varijabilnost i uz 5 µm i uz 20 µm ADP-a.
Do not break or crush the tablet. 
Tablete se ne smiju drobiti niti lomiti.
In patients with acute coronary syndrome (ACS) who are managed with PCI, premature discontinuation of any antiplatelet agent, including Efient, could result in an increased risk of thrombosis, myocardial infarction or death due to the patient's underlying disease. 
U bolesnika s akutnim koronarnim sindromom (engl. acute coronary syndrome, ACS) podvrgnutih PCI-u, prerani prekid primjene bilo kojeg antitrombocitnog lijeka, uključujući Efient, može povećati rizik od tromboze, infarkta miokarda ili smrti kao komplikacije bolesnikove osnovne bolesti.
Patients ≥ 75 years were at increased risk of bleeding, including fatal (see sections 4.2, 4.4, 
Bolesnici u dobi od ≥ 75 godina imali su povećan rizik od krvarenja, uključujući i ona smrtonosna (vidjeti dijelove 4.2, 4.4 i 4.8).
EU/1/08/503/001 14 film-coated tablets EU/1/08/503/002 28 film-coated tablets EU/1/08/503/003 30x1 film-coated tablet EU/1/08/503/004 56 film-coated tablets EU/1/08/503/005 84 film-coated tablets EU/1/08/503/006 90x1 film-coated tablet EU/1/08/503/007 98 film-coated tablets EU/1/08/503/015 30 film-coated tablets 
EU/1/08/503/001 14 filmom obloženih tableta EU/1/08/503/002 28 filmom obloženih tableta EU/1/08/503/003 30x1 filmom obložena tableta EU/1/08/503/004 56 filmom obloženih tableta EU/1/08/503/005 84 filmom obložene tablete EU/1/08/503/006 90x1 filmom obložena tableta EU/1/08/503/007 98 filmom obloženih tableta EU/1/08/503/015 30 filmom obloženih tableta
Similar or higher inhibition of platelet aggregation was observed with prasugrel. 
Uočena je slična ili jača inhibicija agregacije trombocita uz primjenu prasugrela.
a 10 mg prasugrel; 5 mg prasugrel if ≥75 years of age 
a10 mg prasugrela; 5 mg prasugrela ako je dob ≥ 75 godina
Although not studied in specific interaction studies, Efient has been co-administered in the phase 3 clinical trial with low molecular weight heparin, bivalirudin, and GP IIb/IIIa inhibitors (no information available regarding the type of GP IIb/IIIa inhibitor used) without evidence of clinically significant adverse interactions. 
Iako nisu provedena specifična ispitivanja interakcija, Efient se u fazi III kliničkog ispitivanja primjenjivao s heparinom male molekulske mase, bivalirudinom i inhibitorima GPIIb/IIIa (nema podataka o vrsti
Efient showed superior efficacy compared to clopidogrel in reducing the primary composite outcome events as well as the pre-specified secondary outcome events, including stent thrombosis (see Table 3). 
Populacija svih bolesnika s ACS-om: Efient je bio djelotvorniji od klopidogrela u smanjenju broja objedinjenih događaja primarne mjera ishoda kao i unaprijed definiranih događaja koji su činili sekundarne mjere ishoda, uključujući trombozu stenta (vidjeti Tablicu 3).
In TRITON, for every 1000 patients treated with Efient, there were 22 fewer patients with myocardial infarction, and 5 more with non-CABG-related TIMI major haemorrhages, compared with patients treated with clopidogrel. 
U ispitivanju TRITON je na svakih 1000 bolesnika liječenih lijekom Efient broj bolesnika s infarktom miokarda bio manji za 22, dok se broj onih sa značajnim krvarenjem (prema TIMI) nevezanim uz CABG povećao za 5 u usporedbi s bolesnicima liječenima klopidogrelom.
Daily co-administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not change the prasugrel active metabolite's AUC and Tmax, but decreased the Cmax by 14% and 29%, respectively. 
Svakodnevna istodobna primjena ranitidina (blokatora H2-receptora) odnosno lanzoprazola (inhibitora protonske pumpe) s prasugrelom nije dovela do promjene AUC-a i tmax aktivnog metabolita prasugrela, ali je snizila njegov Cmax za 14% odnosno 29%.
• “non steroidal anti inflammatory drugs” for pain and fever (such as ibuprofen, naproxen, etoricoxib). 
• nesteroidnim protuupalnim lijekovima protiv bolova i vrućice (poput ibuprofena, naproksena,
Atorvastatin (80 mg daily) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation. 
Atorvastatin (80 mg na dan) nije promijenio farmakokinetiku prasugrela ni njegovu inhibiciju agregacije trombocita.
Efient, which contains the active substance prasugrel, belongs to a group of medicines called antiplatelet agents. 
Što je Efient i za što se koristi Efient, koji sadrži djelatnu tvar prasugrel, pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
Prasugrel did not inhibit CYP2C9, as it did not affect the pharmacokinetics of S-warfarin. 
Lijekovi koji se metaboliziraju putem CYP2C9: Prasugrel nije inhibirao CYP2C9 jer nije utjecao na farmakokinetiku S-varfarina.
The active metabolite is further metabolised to two inactive compounds by S-methylation or conjugation with cysteine. 
Aktivni metabolit se S-metilacijom ili konjugacijom s cisteinom dalje metabolizira u dva neaktivna spoja.
INFORMATION IN BRAILLE Efient 10 mg 
16. PODACI NA BRAILLEOVOM PISMU Efient 10 mg
The rate of study drug discontinuation due to adverse events was 7.2% for prasugrel and 6.3% for clopidogrel. 
Stopa bolesnika u kojih je zbog nuspojava prekinuta primjena ispitivanog lijeka bila je 7,2% kod primjene prasugrela te 6,3% kod primjene klopidogrela.
MARKETING AUTHORISATION NUMBER(S) Efient 5 mg: 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Efient 5 mg:
Prasugrel is not detected in plasma following oral administration. 
Prasugrel nije utvrđen u plazmi nakon peroralne primjene.
• Low blood platelet count 
• malen broj krvnih pločica
Rates of major bleeding were similar in patients treated with 5 mg prasugrel and those treated with 75 mg clopidogrel. 
Stope značajnih krvarenja bile su slične u bolesnika liječenih prasugrelom u dozi od 5 mg i onih liječenih klopidogrelom u dozi od 75 mg.
Pharmacokinetics and pharmacodynamics of prasugrel in patients with severe hepatic impairment have not been studied. 
Nisu ispitivane farmakokinetika i farmakodinamika prasugrela u bolesnika s teškim oštećenjem jetre.
Also contact your doctor immediately if you notice any of the following: 
Isto tako, odmah se obratite liječniku ako primijetite neke od sljedećih simptoma:
• warfarin (an anti-coagulant), 
• klopidogrelom (antitrombocitni lijek) • varfarinom (antikoagulans)
All of the above may be signs of a stroke. 
Sve to mogu biti znakovi moždanog udara.
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). 
Efient je u kombinaciji s acetilsalicilatnom kiselinom (ASK) indiciran za sprečavanje aterotrombotskih događaja u odraslih bolesnika s akutnim koronarnim sindromom (tj. nestabilnom anginom, infarktom miokarda bez elevacije ST-spojnice [engl. unstable angina, non-ST segment elevation myocardial infarction, UA/NSTEMI] ili infarktom miokarda s elevacijom ST-spojnice [engl.
A single intravenous bolus dose of unfractionated heparin (100 U/kg) did not significantly alter the prasugrel-mediated inhibition of platelet aggregation. 
Jedna doza nefrakcioniranog heparina (100 U/kg) u obliku intravenske bolusne injekcije nije značajno promijenila prasugrelom posredovanu inhibiciju agregacije trombocita.
Pharmacokinetics of prasugrel and its inhibition of platelet aggregation were similar in subjects with mild to moderate hepatic impairment compared to healthy subjects. 
Farmakokinetika prasugrela i njegova inhibicija agregacije trombocita bile su podjednake u ispitanika s blagim do umjerenim oštećenjem jetre i zdravih ispitanika.
In a study of 276 ACS patients managed with PCI, switching from an initial loading dose of 600 mg clopidogrel or placebo administered upon presentation to the hospital prior to coronary angiography to a 60 mg loading dose of prasugrel administered at the time of percutaneous coronary intervention, resulted in a similar increased inhibition of platelet aggregation for the 72 hour duration of the study. 
276 bolesnika s ACS-om podvrgnutih PCI-u, prebacivanje s početne udarne doze od 600 mg klopidogrela ili placeba, primijenjene u trenutku primitka u bolnicu prije koronarne angiografije, na udarnu dozu od 60 mg prasugrela, primijenjenu u vrijeme perkutane koronarne intervencije, dovelo je do podjednakog povećanja inhibicije agregacije trombocita tijekom razdoblja od 72 sata, koliko je trajalo ispitivanje.
Following administration of a 900 mg loading dose of clopidogrel (with ASA), 56 subjects with ACS were treated for 14 days with either prasugrel 10 mg once daily or clopidogrel 150 mg once daily, and then switched to either clopidogrel 150 mg or prasugrel 10 mg for another 14 days. 
Nakon primjene udarne doze klopidogrela od 900 mg (uz ASK), 56 ispitanika s akutnim koronarnim sindromom je 14 dana liječeno ili prasugrelom u dozi od 10 mg jedanput na dan ili klopidogrelom u dozi od 150 mg jedanput na dan, a nakon toga su tijekom sljedećih 14 dana prebačeni na klopidogrel u dozi od 150 mg odnosno prasugrel u dozi od 10 mg.
The MAH should provide educational material to all physicians who may be involved in treating patients with prasugrel. 
MAH mora sve liječnike koji bi mogli biti uključeni u liječenje bolesnika prasugrelom opskrbiti edukacijskim materijalom.
For patients who received their last dose of thienopyridine within 4 to 7 days prior to CABG, the frequencies decreased to 11.3% (9 of 80 patients) in the prasugrel group and 3.4% (3 of 89 patients) in the clopidogrel group. 
7 dana prije CABG-a, učestalost se smanjila na 11,3% (9 od 80 bolesnika) u skupini koja je primala prasugrel, odnosno na 3,4% (3 od 89 bolesnika) u skupini koja je primala klopidogrel.
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva osip ekhimoza
Patients ≥ 75 years in whom the benefit with prasugrel was more evident included those with diabetes, STEMI, higher risk of stent thrombosis, or recurrent events. 
Korist od primjene prasugrela bila je primjetnija u bolesnika u dobi od ≥ 75 godina koji su imali šećernu bolest, STEMI, povećan rizik od tromboze stenta te onih u kojih su se kardiovaskularni događaji ponavljali.
Rare side effects (may affect up to 1 in 1,000 people) 
Rijetke nuspojave (mogu se javiti u do 1 na 1000 osoba):
INFORMATION IN BRAILLE Efient 5 mg 
16. PODACI NA BRAILLEOVOM PISMU Efient 5 mg
Table 2: Haemorrhagic and Non-haemorrhagic adverse reactions System Organ 
Tablica 2: Hemoragijske i nehemoragijske nuspojave Organski sustav Često
Clopidogrel +ASA 
Klopidogrel +ASK
• Subcutaneous haematoma (bleeding under the skin causing a swelling) 
• potkožni hematom (potkožno krvarenje koje uzrokuje oticanje)
The use of oral anticoagulants, non-study antiplatelet medicinal products and chronic NSAIDs was not allowed in TRITON. 
U ispitivanju TRITON nije bila dozvoljena primjena oralnih antikoagulansa, antiagregacijskih lijekova koji nisu bili predmet ispitivanja kao ni kronična primjena NSAIL-a.
It is unknown whether prasugrel is excreted in human breast milk. 
Nije poznato izlučuje li se prasugrel u majčino mlijeko u ljudi.
* ICH=intracranial haemorrhage. 
* IKK = intrakranijalno krvarenje.
See leaflet for further information. 
Za dodatne informacije pročitati uputu o lijeku.
This medicinal product does not require any special temperature storage conditions. 
6.4 Posebne mjere pri čuvanju lijeka Lijek ne zahtijeva čuvanje na određenoj temperaturi.
Elderly: 
Starije osobe:
Platelet aggregation gradually returned to baseline values after treatment in 7 to 9 days after administration of a single 60 mg loading dose of prasugrel and in 5 days following discontinuation of maintenance dosing at steady-state. 
Agregacija trombocita se nakon liječenja postupno vratila na početne vrijednosti, i to za 7 do 9 dana nakon primjene jednokratne udarne doze prasugrela od 60 mg, odnosno za 5 dana nakon prekida primjene doze održavanja u stanju dinamičke ravnoteže.
Patients with STEMI within 12 hours of symptoms and planned for primary PCI could be randomised without knowledge of coronary anatomy. 
Bolesnike koji su imali STEMI i u kojih je planiran PCI, moglo se randomizirati unutar 12 sati od pojave simptoma i bez prethodnog određivanja anatomije koronarnih krvnih žila.
Clopidogrel 
Klopidogrel
OTHER <MON, TUE, WED, THU, FRI, SAT, SUN> 
<PON, UTO, SRI, ČET, PET, SUB, NED>
The reduction in stent thrombosis with Efient was observed both early and beyond 30 days for both bare metal and drug eluting stents. 
Smanjenje broja tromboza stenta kod primjene lijeka Efient opaženo je i u ranoj fazi liječenja kao nakon više od 30 dana, a odnosilo se kako na čiste metalne tako i na stentove koji izlučuju lijek.
The use of Efient in patients ≥ 75 years of age is generally not recommended. 
Primjena lijeka Efient općenito se ne preporučuje u bolesnika u dobi od ≥ 75 godina.
Patients taking Efient should also take ASA daily (75 mg to 325 mg). 
Bolesnici koji uzimaju Efient moraju svakodnevno uzimati i acetilsalicilatnu kiselinu (u dozi od 75 mg do 325 mg).
Of those patients, the rate of CABG-related TIMI major or minor bleeding was 14.1% for the prasugrel group and 4.5% in the clopidogrel group. 
U tih je bolesnika udio značajnih ili manjih krvarenja (prema TIMI kriterijima) vezanih uz CABG bio 14,1% u skupini koja je primala prasugrel te 4,5% u skupini koja je primala klopidogrel.
Prasugrel-mediated inhibition of platelet aggregation was also similar in patients with ESRD who required haemodialysis compared to healthy subjects, although Cmax and AUC of the active metabolite decreased 51% and 42%, respectively, in ESRD patients. 
Prasugrelom posredovana inhibicija agregacije trombocita podjednaka je i u bolesnika u terminalnoj fazi bubrežne bolesti kojima je potrebna hemodijaliza u usporedbi sa zdravim ispitanicima, iako je u bolesnika u terminalnoj fazi bubrežne bolesti Cmax aktivnog metabolita bio 51%, a AUC 42% niži.
Of these, bleeding was the most common adverse reaction for both drugs leading to study drug discontinuation (2.5% for prasugrel and 1.4% for clopidogrel). 
Najčešća nuspojava koja je bila razlogom prekida primjene obaju lijekova bilo je krvarenje (2,5% kod primjene prasugrela i 1,4% kod primjene klopidogrela).
Switching directly to prasugrel 60 mg loading dose resulted in the most rapid onset of higher platelet inhibition. 
Izravnim prebacivanjem na udarnu dozu od 60 mg postignut je najbrži nastup pojačane inhibicije agregacije trombocita.
Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. 
Prasugrel inhibira aktivaciju i agregaciju trombocita ireverzibilnim vezivanjem aktivnog metabolita na ADP receptore tipa P2Y12 na trombocitima.
(see sections 4.2 and 4.4). 
(vidjeti dio 4.4).
Clopidogrelb +ASA (N = 4980) 
Klopidogrelb +ASK (N = 4980)
No compound-related tumours were observed in a 2-year rat study with prasugrel exposures ranging to greater than 75 times the recommended therapeutic exposures in humans (based on plasma exposures to the active and major circulating human metabolites). 
U dvogodišnjem istraživanju na štakorima, uz izloženost prasugrelu koja je bila i do 75 puta veća od preporučene terapijske izloženosti u ljudi (na temelju izloženosti aktivnog i glavnih cirkulirajućih metabolita u plazmi), nije uočena pojava tumora povezana s primjenom lijeka.
How to store Efient 
Kako čuvati Efient
• Skin rash 
• kožni osip
All of the above may be signs of bleeding, the most common side effect with Efient. 
Sve to mogu biti znakovi krvarenja, koje je najčešća nuspojava liječenja lijekom Efient.
The efficacy of prasugrel was independent of the ASA dose (75 mg to 325 mg once daily). 
Djelotvornost prasugrela nije ovisila o dozi ASK-a (75-325 mg jedanput na dan).
Contact your doctor immediately if you notice any of the following: 
Odmah se obratite liječniku ako primijetite neki od sljedećih simptoma:
If prescribed, a lower maintenance dose of 5 mg should be used; the 10 mg maintenance dose is not recommended (see sections 4.2 and 4.8). 
Doza održavanja od 10 mg se ne preporučuje (vidjeti dijelove 4.2 i 4.8).
• A rash, itching, or a swollen face, swollen lips/tongue, or shortness of breath. 
• osip, svrbež, oticanje lica, oticanje usana ili jezika ili nedostatak zraka.
Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation. 
Stoga se ne predviđa da će statini koji su supstrati CYP3A utjecati na farmakokinetiku prasugrela ili na inhibiciju agregacije trombocita ovim lijekom.
Common side effects (may affect up to 1 in 10 people) 
Česte nuspojave (mogu se javiti u do 1 na 10 osoba):
Clopidogrelb +ASA (N = 1736) 
Klopidogrelb +ASK (N = 1736)
The benefit was primarily due to a significant decrease in non-fatal MI (see Table 3). 
Korist se primarno temeljila na značajnom smanjenju broja nesmrtonosnih infarkta miokarda (vidjeti
• Blood in stools 
• krv u stolici
In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients ≥75 years old taking 5 mg prasugrel was approximately half that in patients < 65 years old taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was reduced but was non-inferior compared to 10 mg. 
U ispitivanju u kojem su sudjelovali ispitanici sa stabilnom aterosklerozom, srednja vrijednost AUC-a aktivnog metabolita u bolesnika u dobi od ≥ 75 godina liječenih prasugrelom u dozi od 5 mg bila je približno dvostruko manja nego u bolesnika mlađih od 65 godina liječenih prasugrelom u dozi od 10 mg, dok je antitrombocitni učinak doze od 5 mg bio manji, ali ne i inferioran u odnosu na dozu od 10 mg.
In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients <60 kg taking 5 mg prasugrel was 38% lower than in patients ≥60 kg taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was similar to 10 mg. 
U ispitivanju u kojem su sudjelovali ispitanici sa stabilnom aterosklerozom, srednja vrijednost AUC-a aktivnog metabolita u bolesnika tjelesne težine < 60 kg koji su uzimali prasugrel u dozi od 5 mg bila je 38% niža nego u bolesnika tjelesne težine ≥ 60 kg koji su uzimali prasugrel u dozi od 10 mg, dok je antitrombocitni učinak doze od 5 mg bio podjednak učinku doze od 10 mg.
Injury, poisoning and procedural complications 
Ozljede, trovanja i proceduralne komplikacije kontuzija postproceduralno krvarenje potkožni hematom
Do not take Efient - If you are allergic (hypersensitive) to prasugrel or any of the other ingredients of Efient. 
- ako ste alergični (preosjetljivi) na prasugrel ili neki drugi sastojak lijeka Efient.
As in the < 75 years old and ≥60 kg patients treated with 10 mg prasugrel, there was no difference between 5 mg prasugrel and 75 mg clopidogrel in CV outcomes. 
Kao i u bolesnika u dobi od < 75 godina i onih tjelesne težine ≥ 60 kg koji su uzimali dozu prasugrela od 10 mg, nije primijećena razlika između prasugrela u dozi od 5 mg i klopidogrela u dozi od 75 mg kada su u pitanju kardiovaskularni ishodi.
1.2% (0% ICH*) 
1,2% (0% IKK*)
Primary Individual Outcome Events 
Objedinjeni događaji iz primarne mjere ishoda:
Therapeutic experience with prasugrel is limited in patients with renal impairment (including ESRD) and in patients with moderate hepatic impairment. 
Ograničeno je terapijsko iskustvo s prasugrelom u bolesnika s oštećenjem bubrega (uključujući one u terminalnoj fazi bubrežne bolesti) te u bolesnika s umjerenim oštećenjem jetre.
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
PRILOG II. A. PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
Uncommon side effects (may affect up to 1 in 100 people) 
Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba):
Statins: 
Statini: